## 3 Results
### The HfrD Did Not Affect TC, HDL, and LDL Levels  
On Day 29, TC, HDL, and LDL levels were monitored. An 8.29 mg/dL increase in TC levels of the HfrD control group was recorded (Table 3). However, such an increase was not statistically significant compared to the normal group. A significant decrease in TC levels was observed in the omega-3 group (Table 3). HDL levels dropped in most groups, except the EPK 125 and 250 groups. Lastly, LDL levels increased in the HfrD group, but the increase was not statistically significant compared with that of the other groups (Table 3). \begin{table}
\begin{tabular}{c c c c} \hline \hline  & \multicolumn{3}{c}{**Time after Administration (Days)**} \\ \cline{2-4}
**Group** & \multicolumn{3}{c}{**Body Weight (g)**} \\ \cline{2-4}  & **Day1** & **Day22** & **Day1** & **Day22** \\ \hline N & 427.08 \(\pm\) 31.83 & 538.16 \(\pm\) 47.62 & +25.92 \(\pm\) 3.65 \\ HfrD & 418.27 \(\pm\) 9.82 & 530.20 \(\pm\) 28.36 & +26.76 \(\pm\) 6.07 \\ EPK 60 & 405.36 \(\pm\) 17.08 & 503.16 \(\pm\) 16.79 & +24.74 \(\pm\) 1.90 \\ EPK 125 & 390.32 \(\pm\) 16.53 & 492.51 \(\pm\) 29.85 & +26.21 \(\pm\) 6.51 \\ EPK 250 & 408.18 \(\pm\) 14.16 & 518.51 \(\pm\) 26.61 & +27.01 \(\pm\) 4.27 \\ Omega-3 & 417.59 \(\pm\) 9.94 & 510.38 \(\pm\) 44.97 & +22.34 \(\pm\) 11.77 \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Body weight in experimental groups. \begin{table}
\begin{tabular}{c c c c c c c c c c} \hline \hline  & \multicolumn{6}{c}{**Concentration (mg/dL)/Time after Administration (Days)**} \\ \cline{2-9}  & \multicolumn{3}{c}{**Total Cholesterol**} & \multicolumn{3}{c}{**HDL-C**} & \multicolumn{3}{c}{**LDL-C**} \\ \cline{2-9}
**Group** & \multicolumn{3}{c}{**Day1**} & **Day29** & **\begin{tabular}{c} **\% of Total** \\ **Cholesterol** \\ **Change** \\ \end{tabular} & **Day1** & **Day29** & **\
\begin{tabular}{c} **\% of HDL-C** \\ **Change** \\ \end{tabular} & **Day1** & **Day29** & **
\begin{tabular}{c} **\% of LDL-C** \\ **Change** \\ \end{tabular} \\ \hline N & 102 \(\pm\) 14.42 & 100.29 \(\pm\) 15.84 & \(-\)1.13 \(\pm\) 13.95 & 33.46 \(\pm\) 3.86 & 29.21 \(\pm\) 3.97 & \(-\)12.24 \(\pm\) 10.65 & 9.82 \(\pm\) 1.58 & 9.36 \(\pm\) 2.96 & \(-\)5.80 \(\pm\) 17.73 \\ HfrD & 82.57 \(\pm\) 13.21 & 90.86 \(\pm\) 10.14 & +11.97 \(\pm\) 18.07 & 29.18 \(\pm\) 3.64 & 27.9 \(\pm\) 2.42 & \(-\)2.00 \(\pm\) 13.87 & 5.84 \(\pm\) 0.80 & 6.98 \(\pm\) 1.38 & +18.92 \(\pm\) 10.47 \\ EPK 60 & 89.57 \(\pm\) 12.81 & 85.14 \(\pm\) 10.52 & -4.09 \(\pm\) 16.18 & 33.21 \(\pm\) 5.89 & 27.2 \(\pm\) 4.87 & -14.52 \(\pm\) 13.87 & 5.78 \(\pm\) 1.86 & 5.7 \(\pm\) 1.45 & +0.44 \(\pm\) 16.66 \\ EPK 125 & 85.86 \(\pm\) 16.43 & 92.71 \(\pm\) 20.69 & +8.58 \(\pm\) 16.03 & 30.65 \(\pm\) 5.06 & 32.87 \(\pm\) 6.11 & +6.81 \(\pm\) 16.61 & 5.62 \(\pm\) 0.49 & 6.06 \(\pm\) 0.79 & +8.10 \(\pm\) 13.70 \\ EPK 250 & 86.57 \(\pm\) 2.88 & 94.43 \(\pm\) 21.53 & +9.42 \(\pm\) 26.77 & 33.58 \(\pm\) 1.82 & 30.99 \(\pm\) 3.94 & \(-\)7.65 \(\pm\) 15.92 & 5.42 \(\pm\) 0.98 & 5.9 \(\pm\) 0.65 & +10.24 \(\pm\) 12.89 \\ Omega-3 & 90.71 \(\pm\) 9.23 & 71.29 \(\pm\) 3.95 & \(-\)20.49 \(\pm\) 11.54 & 33.56 \(\pm\) 2.15 & 25.65 \(\pm\) 1.83 & \(-\)24.41 \(\pm\) 7.58 & 5.58 \(\pm\) 0.67 & 5.8 \(\pm\) 0.58 & +4.31 \(\pm\) 6.57 \\ \hline \hline \end{tabular}
\end{table} 
Table 3: Serum lipid markers in experimental groups. EPK Decreased Serum and Hepatic TG Levels and Increased TG Excretion through Feeces in High Fructose-Induced Hypertriglyceridemia Animal Models  
To induce hypertriglyceridemia in the HFrD control, EPK 60, 125, 250, and omega-3 groups, they were given an HFrD (Research Diet, New Brunswick, NJ, USA) for two weeks, before undergoing drug treatment. In Week 3, they were administered with EPK, omega-3, or vehicle by oral gavage, and this procedure was performed for the next four weeks. Serum TG levels were measured on Days 1, 14, and 29. On Day 1, serum TG levels were elevated in all groups fed with HFrD, except in the normal group. For instance, the TG levels of the HFrD control group were two-fold higher than that of the normal group.